Characterization of Adverse Cutaneous Effects in the Setting of Ponatinib, Bosutinib, and Asciminib for Chronic Myeloid Leukemia Patients.

bosutinib - Generic mfg.

Iclusig (ponatinib) - Takeda

Scemblix (asciminib) - Novartis

Characterization of Adverse Cutaneous Effects in the Setting of Ponatinib, Bosutinib, and Asciminib for Chronic Myeloid Leukemia Patients. (PubMed, Hematol Oncol) - Oct 21, 2026 - No abstract available
Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42899371

Goranit Sakunchotpanit; Juna Khang; Nicole R LeBoeuf; Ruhi Kanwar; Ruhi Nayak; Vinod E Nambudiri

Oct 21, 2026